Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047769 | 0.88 | HDAC1 (0.40) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL7046400 | 0.80 | PTGER4 (0.38) | HDAC1HDAC6MAPTHDAC3HDAC2 | |
| SCHEMBL7185046 | 0.78 | HSP90AA1 (0.38) | HDAC1HDAC6MAPTHDAC3HDAC2 | |
| SCHEMBL7049142 | 0.78 | ANPEP (0.37) | HDAC1HDAC6MAPTHDAC3HDAC2 | |
| SCHEMBL7045972 | 0.77 | TP53 (0.38) | HDAC1HDAC6MAPTHDAC3HDAC2 | |
| SCHEMBL7046902 | 0.77 | HSP90AA1 (0.40) | HDAC1HDAC6MAPTHDAC3HDAC2 | |
| SCHEMBL7042861 | 0.77 | FOLH1 (0.36) | MAPTPTGER4FOLH1 | |
| SCHEMBL7042122 | 0.77 | FOLH1 (0.35) | HDAC1HDAC6MAPTPTGER4FOLH1 | |
| SCHEMBL7049411 | 0.76 | TLR2 (0.38) | MAPTPTGER4FOLH1 | |
| SCHEMBL16785551 | 0.70 | HDAC1 (0.45) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | HDAC1 304/4885HDAC6 217/4885MAPT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.